BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. is a biotechnology company focused on the research, development, and commercialization of cellular therapies, primarily utilizing adult stem cells. Headquartered in Melville, New York, the company's mission is to develop innovative stem cell-based treatments to address unmet medical needs in patients suffering from highly prevalent conditions. Founded in 1997, the company was formerly known as Stem Cell Assurance, Inc. before changing its name in August 2011.

BioRestorative Therapies operates with two core clinical development programs and a commercial platform. Its Disc/Spine Program features BRTX-100, an autologous cultured mesenchymal stem cell therapy designed for the non-surgical treatment of painful lumbosacral disc disorders, specifically chronic lumbar disc disease (cLDD). The ThermoStem® program focuses on metabolic disorders, including obesity and Type 2 Diabetes, using brown adipose-derived stem cells. Additionally, the company has a commercial BioCosmeceutical platform exploring aesthetic medicine applications, including a proprietary serum for fine lines and wrinkles.

Under the leadership of CEO Lance Alstodt, BioRestorative Therapies has achieved several recent milestones. In February 2026, the company completed enrollment for its Phase 2 clinical trial of BRTX-100 for cLDD, and subsequently reported positive blinded data in March 2026, demonstrating meaningful improvements in pain and function. The company also announced a strategic collaboration in April 2026 to advance its BioCosmeceutical platform. In October 2025, the Japanese Patent Office issued a Notice of Allowance for the ThermoStem® platform, providing broad intellectual property protection for its technology.